Karuna Therapeutics Profit Margin

Karuna Therapeutics (KRTX) currently reports a profit margin of -64554.74% as of December 2023. That compares with -2597.88% in the prior-year period — down 2384.9% year over year. That is below the Healthcare sector average of 13.89%. Use the charts on this page to explore Karuna Therapeutics's profit margin history and peer comparisons.

Karuna Therapeutics's profit margin decreased from -2597.88% to -64554.74% — a 2384.9% year-over-year decrease (period ending December 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Karuna Therapeutics's profit margin of -64554.74% is lower than the Healthcare sector average of 13.89%. That is roughly 464851.6% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Karuna Therapeutics's current -64554.74% should be judged against Healthcare norms (sector average: 13.89%) and against KRTX's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -64554.74%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 13.89%. From there, open related valuation or income-statement pages for Karuna Therapeutics, and consider following KRTX for alerts when major investors trade the stock.